Lineage Cell Therapeutics, Inc. released its earnings results on Aug 10, 2023. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.014.

Is Lineage Cell Therapeutics, Inc. overvalued?

According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lineage Cell Therapeutics, Inc. pay dividends?

Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of $0.11 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here

What is Lineage Cell Therapeutics, Inc.’s EPS estimate?

Lineage Cell Therapeutics, Inc.’s EPS estimate is -$0.05.

How many shares outstanding does Lineage Cell Therapeutics, Inc. have?

Lineage Cell Therapeutics, Inc. has 174,986,660 shares outstanding.

What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?

Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 2.128%.

Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?

Among the largest hedge funds holding Lineage Cell Therapeutics, Inc.’s share is Defender Capital, LLC.. It holds Lineage Cell Therapeutics, Inc.’s shares valued at 7M.

---

Lineage Therap Stock Smart Score

Outperform

Fundamentals

Return on Equity

-28.32%

Trailing 12-Months

Asset Growth

-17.83%

Trailing 12-Months

The Lineage Therap stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Learn more about TipRanks Smart Score

Go to Top Smart score Stocks >

Company Description

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

---